Trellus Health, a resilience-driven digital health solution for chronic conditions, today announced that it has raised $5 million of seed funding to transform the way chronic conditions are treated, with an initial focus in Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
| NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Trellus Health, a resilience-driven digital health solution for chronic conditions, today announced that it has raised $5 million of seed funding to transform the way chronic conditions are treated, with an initial focus in Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. The round was led by Mount Sinai Health System (MSHS) and EKF Diagnostics, a global medical manufacturer of point-of-care and central lab devices and tests. Trellus has also entered into an exclusive multi-year contract with MSHS to commercialize its patent pending GRITT-IBDTM resilience assessment and personalized treatment methodology.
Ninety-percent of the United States’ $3.3 trillion annual health care expenditure is for chronic diseases, with patients suffering from both chronic medical and mental health conditions costing twice as much, according to the CDC. Despite these cost implications, traditional care models fail to address the emotional well-being of people with chronic conditions, and access to expert interdisciplinary care resources to deliver specialist-level care is highly limited. “We are transforming the way chronic conditions are treated by developing a resilience-driven connected care platform that integrates precision medicine with psychosocial care,” said Monique Fayad, CEO of Trellus Health. “The traditional journey of medical care for people living with chronic conditions typically results in repeated costly, unplanned emergency room visits and hospitalizations, high rates of work absenteeism and lost productivity, as well as chronic disability and behavioral health issues. We’re working to change this by focusing on building patients’ resilience while integrating all partners in care, including employers, insurance plans, health systems, Trellus-certified GI providers, nurses, psychologists, and dieticians who can utilize Trellus Health’s proprietary platform to effectively monitor and communicate with patients and their caregivers in real time.” The first chronic condition that Trellus Health will address is IBD, one of the costliest chronic conditions with a high mental health burden, affecting 3 million patients in the U.S. (7 million globally) and costing the U.S. healthcare system over $30 billion a year, according to the Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation 2019. Since 2016, the company’s co-founders, Marla Dubinsky, MD, and Laurie Keefer, PhD, who together bring close to 50 years of experience managing IBD and serve as co-directors of the Mount Sinai IBD Medical Home, have integrated resilience-driven multi-disciplinary care into the management of IBD patients. “Our research on over 200 IBD patients indicates that more than 70% believe their condition would be better managed if they had support for anxiety or depression,” said Dubinsky, who along with being a co-founder and board member, is also a Professor of Pediatrics and Medicine, Chief of Division of Pediatric Gastroenterology and co-director of Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai. “By personalizing care to address the psychosocial needs of all IBD patients and applying the latest evidence-based clinical approaches, we can help patients achieve disease control and enjoy a significantly improved quality of life.” Resilience-driven care incorporates positive psychology principles into all aspects of chronic disease management, with a focus on building acceptance, optimism, self-regulation, self-efficacy, and social support. Proven health benefits of resilience include increased longevity, cardiovascular, immune, and cognitive function, as well as physical well-being and reduced risk for depression and anxiety. “Crohn’s disease was discovered at Mount Sinai by Dr. Burrill Crohn nearly 100 years ago, and the System has made great strides in enhancing the the standard of care and outcomes for our patients,” said Erik Lium, President, Mount Sinai Innovation Partners and Executive Vice President and Chief Commercial Innovation Officer at Mount Sinai. “We’re pleased to partner with Trellus Health to advance commercial development of a resilience-driven approach and connected care model for treating IBD and other complex chronic conditions, making Mount Sinai’s technology available to more patients.” “Dr. Keefer’s important research utilizing the GRITTTM Method at the Mount Sinai IBD Center shows first-hand how resilience-driven multidisciplinary care significantly reduces unplanned care,” said Julian Baines, CEO of EKF Diagnostics. “We are excited to support Trellus in helping millions of people reduce their disease burden and improve their overall well being.” About Trellus Health The resilience-driven connected care solution described is based on technology developed by Mount Sinai faculty and licensed to Trellus Health. Mount Sinai and Mount Sinai faculty members Marla Dubinsky, MD, and Laurie Keefer, PhD, have a financial interest in Trellus Health. About the Mount Sinai Health System For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube. About Mount Sinai Innovation Partners (MSIP) About EKF Diagnostics
SOURCE Trellus Health |
View original content to download multimedia:
